Health technology assessment (HTA) can scientifically identify the clinical value of innovative high-value consumables and provide an evidence-based basis for health insurance access decision-making. HTA in the field of medical consumables starts late in China, and there are no mature guidelines or application specifications. Based on the analysis at home and abroad, it is suggested that we can explore the classification of assessment, and carry out HTA for innovative high-value consumables with high degree of innovation, high therapeutic cost, and significant impact on the fund. At the same time, we should pay attention to the special characteristics of consumables, differentiate the design of the key techniques of HTA, choose more blank references, refer to real-world data, use cost-consequence analysis (CCA), consider parameters such as training/maintenance costs, and consider the effects of learning curve. When making decisions on medical insurance access, HTA should be used to assist decision-making, and in a few cases where the assessment results are sufficiently sound and the market is stable, the results of the HTA can be considered as the main basis for decision-making.
Key words
HTA /
innovative high-value consumable /
medical insurance access
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 王锐,李佳明,李伟,等.高值医用耗材医保准入的分类评估机制研究[J].中国医疗保险,2024(06):21-28.
[2] CHEN WEN, ZHANG LUYING, HU MIN, et al.Use of health technology assessment in drug reimbursement decisions in China[J]. BMJ, 2023 (7):381.
[3] 保健医療経済評価研究センター.【Micra 経カテーテルペーシングシステム(Micra AV)】に 関する公的分析の結果[EB/OL].(2023-07-22)[2024-07-21].https://c2h.niph.go.jp/results/C2H2112/C2H2112_Report.pdf.
[4] 牛云茜,柯于梵,易敏慈.Micra™无导线起搏器临床应用的前瞻性研究[J].中华老年医学杂志,2020,39(07):787-790.
[5] MIKHAEL F EL-CHAMI, JENS BROCK JOHANSEN, AMIR ZAIDI, et al. Leadless pacemaker implant in patients with pre-existing infections: results from the Micra postapproval registry[J]. Journal of cardiovascular electrophysiology, 2019, 30(4) : 569-574.
[6] 厚生労働省.医療機器の保険適用について[EB/OL].(2019-12)[2024-06-19].https://www.mhlw.go.jp/content/12404000/000550466.pdf.
[7] 厚生労働省.医薬品・医療機器等の費用対効果評価案について[EB/OL].(2023-06-14)[2024-06-19].https://www.mhlw.go.jp/content/12404000/001107252.pdf.
[8] 厚生労働省.費用対効果評価について 骨子(案)[EB/OL].(2019-04-12)[2024-06-19].https://www.mhlw.go.jp/content/12404000/000481013.pdf.
[9] 国家医疗保障局. 2023年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的申报药品信息[EB/OL].(2023-08-18)[2024-07-26].https://www.nhsa.gov.cn/art/2023/8/18/art_152_11182.html.
[10] 徐英,张雷.单病种管理中耗占比监测的作用分析[J].中国医疗设备,2020,35(02):126-129.
[11] NICE. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke[EB/OL].[2024-07-16].https://www.nice.org.uk/guidance/dg41/chapter/2-The-diagnostic-tests.
[12] MURAD M H, ASI N, ALSAWAS M, et al.New evidence pyramid[J]. BMJ evidence-based medicine, 2016,21(4):125-127.
[13] DRUMMOND M F, TARRICONE R, TORBICA A.Economic evaluation of medical devices[Z]. 2018.
[14] NICE. Published guidance, NICE advice and quality standards-medical technologies guidance[EB/OL].(2023-07-25)[2023-11-29].https://www.nice.org.uk/guidance/published?ngt=Medical%20technologies%20guidance&ndt=Guidance.
[15] NICE. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care[EB/OL].(2019-05)[2024-07-11].https://www.nice.org.uk/guidance/dg35.
[16] O'BRIEN B.Methods for the economic evaluation of health care programmes[M]. Oxford University Press, 1997.
[17] TURNER H C, ARCHER R A, DOWNEY L E, et al.An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations[J]. Frontiers in public health,2021,8(9): 722927.
[18] Office for Health Improvement and Disparities. Cost consequence analysis: health economic studies[EB/OL].(2020-07-22)[2024-07-25].https://www.gov.uk/guidance/cost-consequence-analysis-health-economic-studies.
[19] Office for Health Improvement and Disparities. Cost utility analysis: health economic studies[EB/OL].(2020-10-13)[2024-07-25].https://www.gov.uk/guidance/cost-utility-analysis-health-economic-studies.
[20] D VOHORA, G SINGH.Pharmaceutical medicine and translational clinical research[M]. Cambridge: Academic Press, 2018: 465-472.
[21] 马越,徐雨婷,魏琪然,等.医用耗材经济性评价方法研究及启示——基于各国医疗器械经济性评价指南[J].卫生经济研究,2022,39(11):55-60.
[22] NICE. Plus sutures for preventing surgical site infection[EB/OL].(2021-06-28)[2024-07-16].https://www.nice.org.uk/guidance/mtg59.
[23] MING J, HE Y, YANG Y, et al.Health technology assessment of medical devices: current landscape, challenges, and a way forward[J]. Cost effectiveness and resource allocation, 2022:54.
[24] NICE. iFuse for treating chronic sacroiliac joint pain[EB/OL].(2022-08-30)[2023-12-22]. https://www.nice.org.uk/guidance/mtg39.
[25] WU O, MCCARTNEY E, HEGGIE R, et al.Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT[J]. Health technology assessment, 2021,25(47):1-126.
[26] TARRICONE R, CALLEA G, OGOREVC M, et al.Improving the methods for the economic evaluation of medical devices[J].Health economics, 2017 (1):70-92.
[27] STEFAAN MULIER, YICHENG NI, JACQUES JAMART, et al.Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors[J]. Annals of surgery, 2005, 242(2):158-71.
[28] NICE. Danis stent for acute oesophageal variceal bleeding[EB/OL].(2021-03-31)[2024-07-11].https://www.nice.org.uk/guidance/mtg57.
[29] 保健医療経済評価研究センター. 経カテーテルウシ心のう膜弁 (サピエンXT)[EB/OL].(2019-03-27)[2024-07-11].https://c2h.niph.go.jp/results/2019_07/index.html.
